Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424121 | 1.00 | CALML3 (0.46) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL709604 | 1.00 | CALML3 (0.46) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL541127 | 0.96 | CALML3 (0.47) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL541126 | 0.96 | CALML3 (0.47) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL2109046 | 0.91 | MAOA (0.49) | CALML3MAOAMAOB | |
| SCHEMBL2109045 | 0.87 | RORC (0.35) | CYP2C19PIK3R1PIK3CARORCPDE4B | |
| SCHEMBL701777 | 0.86 | MAOA (0.51) | CALML3MAOAMAOB | |
| SCHEMBL541400 | 0.84 | CALML3 (0.47) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL541401 | 0.84 | CALML3 (0.47) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL6398565 | 0.82 | CALML3 (0.51) | CALML3MAOAMAOBCYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124623-B2 | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-28 | — | — | US | disclosed |
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | OGFOD1, OXGR1, ODC1 | CALML3 3066/4885MAOA 447/4885MAOB 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.